GSK Files For Approval Of First New Generation Drug Lamictal For Epilepsy In Japan
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline filed for approval of its anti-epilepsy Lamictal (lamotrigine) as a single-agent therapy for adult tonic-clonic and partial seizures in Japan, the company announced on Sept. 12.